Frontline Therapy of Severe Aplastic Anaemia with Fludarabine, Cyclophosphamide and Ciclosporin

Qingguo Liu,Xin Zhao,Ning Xu,Pingping Huang,Shangzhu Li,Fengkui Zhang,Jianxiang Wang

DOI: https://doi.org/10.1111/bjh.13396

2015-01-01

British Journal of Haematology

Abstract:Acquired aplastic anaemia (AA) represents the failure of haematopoiesis resulting in a hypocellular bone marrow and pancytopenia. Severe aplastic anaemia (SAA) has a high rate of mortality without treatment. Antithymocyte globulin (ATG) and ciclosporin (CsA)-based immunosuppressive therapy is the standard treatment for SAA patients who are not eligible for haematopoietic stem cell transplantation (Scheinberg & Young, 2012), but the response is often incomplete and the cost of a course of ATG is too high for the patients in less developed countries. Moderate-dose cyclophosphamide is effective and cheap for treating SAA, but its toxicity and safety are debatable (Brodsky et al, 2010; Zhang et al, 2013; Scheinberg et al, 2014). Fludarabine is highly selective on lymphocytes and in vitro study on lymphocytes in chronic lymphocytic leukaemia showed that fludarabine inhibits repair of cyclophosphamide-induced DNA interstrand cross links, thus combination of cyclophosphamide with fludarabine produced more additive apoptotic cell death than the sum of each alone (Yamauchi et al, 2001). Based on past experience, we conducted a small scale study with eight SAA patients between September 2012 and October 2013 who received fludarabine, cyclophosphamide and CsA (FCC) as frontline therapy. The study was approved by Institutional Review Board of Blood Disease Hospital and was conducted in accordance with the Declaration of Helsinki. All of the patients or their legal guardians provided signed informed consent. Fludarabine was used at 50 mg/d intravenously for 5 d and cyclophosphamide was used at 10 mg/kg/d intravenously for 4 d. Additional cyclophosphamide of 10 mg/kg/week (range, 2–7 times) was used until the patient achieved transfusion-independence or emerging toxicity. Oral CsA was administered every 8 h and adjusted to maintain a serum level of 200–400 ng/ml or based on renal toxicity or tolerance. The protocol is demonstrated in Figure S1. Red cell and platelet transfusions were performed to maintain a haemoglobin level >70 g/l and platelet count >20 × 109/l. Broad-spectrum antibiotics were administered at first fever and adjusted according to microbial cultures and imaging studies. Criteria for haematological response was in accordance with the current definition (Marsh et al, 2009) and the toxicity of the protocol was evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf). Five males and three females with a median age of 35·5 (14–65) years were enrolled in this study. Patient characteristics are shown in Table 1. Patient 2 also had mixed connective tissue disease, hepatic cirrhosis and esophageal varix. Among the three patients (Patients 3, 4 and 6) with Grade 3 infections at the time of hospitalization, Patient 4 was diagnosed with pulmonary fungal infection according to the clinical symptoms and image result. At admission, two patients (Patients 3 and 5) had received CsA alone or with granulocyte-colony stimulating factor for 1 and 2·5 months, respectively. The median follow-up time was 12 (range, 5–18) months with all patients achieving haematological response within 6 months (Table 1 and Fig 1). The median time to reach neutrophil count ≥0·5 × 109/l and platelet count ≥20 × 109/l was 20·5 (2–57) d and 35 (20–90) d, respectively. Total medical cost was US $12 919 (US $8115–36 646). Patient 2 ceased oral CsA after 4 months due to haemorrhage from esophageal varices. Her last follow-up was at 5 months and by that time she had became transfusion-dependent again. The median haemoglobin concentration, neutrophil count and platelet count of the other seven patients at last follow-up were 124 (85–143) g/l, 1·79 (1·53–3·55) × 109/l and 140 (77–319) × 109/l, respectively, and two patients achieved complete haematological response. The lymphocyte percentage and absolute count decreased significantly at 1 week after treatment. Lymphocyte subtypes analysis showed that CD3+ CD4+ T lymphocytes reduced significantly and remained at a low level for a long time (Figure S2). The bone marrow was ameliorated significantly at 6 months. Five patients showed an increased bone marrow cellularity and four patients were tested for bone marrow stem/progenitor cell colony-forming assay and showed great improvement (Figure S3). Paroxysmal nocturnal haemoglobinuria clone, lymphoma or abnormal karyotype was not noted in any of the patients. All patients tolerated the FCC regimen well. No functional damage of organs, such as liver, heart and kidney, was noted. Three patients (Patients 1, 5, 7) developed Grade 3 gastrointestinal infections, which was combined with Grade 3 pulmonary infection in Patient 5. All the infections were under control and cured. Patient 8 suffered from haemorrhagic cystitis and alopecia. The reported overall response rate of AA to CsA alone (Marsh et al, 1999), ATG + CsA (Bacigalupo et al, 2000; Scheinberg et al, 2011; Zhang et al, 2013) and cyclophosphamide + CsA (Brodsky et al, 2010; Zhang et al, 2013; Scheinberg et al, 2014) were reported to be 46%, 37–78% and 41–73%, respectively. The response rate in this study is 8/8 (100%), higher than the previous reports. Although the true response rate maybe somewhat biased due to the small sample size, the study still showed inspiring prospect of using FCC regimen in the treatment of SAA. FCC effectively and quickly depleted lymphocytes, especially CD4+ T cells, which are the primary Th1 cytokine-secreting lymphocytes. The strong immunosuppression and reduced transfusion rate may contribute to the better recovery of haematopoiesis (Piccin et al, 2010). This report highlights the good response of SAA to FCC, the favourable toxicity profile, and the rapid onset of clinical response. In addition, patients in this study were treated in ordinary wards, without the support of high-efficiency particulate air filtration system during the neutropenic period. This means FCC could be carried out as soon as SAA is diagnosed, even in less developed countries or secondary hospitals. It could serve as an alternative to ATG for SAA patients, especially those who are not eligible for haematopoietic stem cell transplantation, without health insurance and cannot afford the cost of ATG. The authors would like to acknowledge Dr. Xingmin Feng for his valuable suggestions on writing the manuscript. QL was the principal investigator. QL and XZ analysed data and wrote the manscript. QL, NX, PH, SL contributed to patient recruitment and treatment. FZ was involved in the conceptualization of the protocols, interim discussions and writing of the manuscript. JW was involved in the interim discussions and interpretation of results. The authors declare no conflict of interest. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.